Despite beginning therapeutic immunizations at 6 weeks post infection, CD154+ activated, vaccine-specific CD4+ T cells from cohorts of mice receiving ID93/GLA-SE were not significantly different from RHZ treatment alone until week 12 (Figure 2). The gene discussed is CD4; the disease is infection.